Advanced search options

Advanced Search Options 🞨

Browse by author name (“Author name starts with…”).

Find ETDs with:

in
/  
in
/  
in
/  
in

Written in Published in Earliest date Latest date

Sorted by

Results per page:

Sorted by: relevance · author · university · dateNew search

You searched for subject:(Everolimus). Showing records 1 – 30 of 46 total matches.

[1] [2]

Search Limiters

Last 2 Years | English Only

Languages

▼ Search Limiters


Ruhr Universität Bochum

1. Wasgien, Mirko. Vergleich der Effizienz und Sicherheit des mTOR-Inhibitoren Everolimus in höherer und niedriger Dosierung bei herztransplantierten Patienten mit chronischer Niereninsuffizienz.

Degree: 2014, Ruhr Universität Bochum

 Wir untersuchten zwei herztransplantierte Patientengruppen mit chronischer Niereninsuffizienz, die mit verschiedenen Dosierungen des Immunsuppressivums Everolimus behandelt wurden. Der primäre Endpunkt unserer Studie war ein kombinierter… (more)

Subjects/Keywords: Immunsuppression; Herztransplantation; Niereninsuffizienz; Everolimus; Transplantatabstoßung

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Wasgien, M. (2014). Vergleich der Effizienz und Sicherheit des mTOR-Inhibitoren Everolimus in höherer und niedriger Dosierung bei herztransplantierten Patienten mit chronischer Niereninsuffizienz. (Thesis). Ruhr Universität Bochum. Retrieved from http://nbn-resolving.de/urn/resolver.pl?urn=urn:nbn:de:hbz:294-41708

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16th Edition):

Wasgien, Mirko. “Vergleich der Effizienz und Sicherheit des mTOR-Inhibitoren Everolimus in höherer und niedriger Dosierung bei herztransplantierten Patienten mit chronischer Niereninsuffizienz.” 2014. Thesis, Ruhr Universität Bochum. Accessed April 16, 2021. http://nbn-resolving.de/urn/resolver.pl?urn=urn:nbn:de:hbz:294-41708.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7th Edition):

Wasgien, Mirko. “Vergleich der Effizienz und Sicherheit des mTOR-Inhibitoren Everolimus in höherer und niedriger Dosierung bei herztransplantierten Patienten mit chronischer Niereninsuffizienz.” 2014. Web. 16 Apr 2021.

Vancouver:

Wasgien M. Vergleich der Effizienz und Sicherheit des mTOR-Inhibitoren Everolimus in höherer und niedriger Dosierung bei herztransplantierten Patienten mit chronischer Niereninsuffizienz. [Internet] [Thesis]. Ruhr Universität Bochum; 2014. [cited 2021 Apr 16]. Available from: http://nbn-resolving.de/urn/resolver.pl?urn=urn:nbn:de:hbz:294-41708.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Wasgien M. Vergleich der Effizienz und Sicherheit des mTOR-Inhibitoren Everolimus in höherer und niedriger Dosierung bei herztransplantierten Patienten mit chronischer Niereninsuffizienz. [Thesis]. Ruhr Universität Bochum; 2014. Available from: http://nbn-resolving.de/urn/resolver.pl?urn=urn:nbn:de:hbz:294-41708

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation


University of Sydney

2. Basnett, Jordan. Characterisation of Resistance to Everolimus in Acute Lymphoblastic Leukemia .

Degree: 2016, University of Sydney

 Acute Lymphoblastic Leukemia (ALL) is the most common childhood cancer. Disease relapse following treatment still occurs in a significant minority of children and the majority… (more)

Subjects/Keywords: Everolimus; MTOR; ALL Leukemia; Resistance

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Basnett, J. (2016). Characterisation of Resistance to Everolimus in Acute Lymphoblastic Leukemia . (Thesis). University of Sydney. Retrieved from http://hdl.handle.net/2123/16332

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16th Edition):

Basnett, Jordan. “Characterisation of Resistance to Everolimus in Acute Lymphoblastic Leukemia .” 2016. Thesis, University of Sydney. Accessed April 16, 2021. http://hdl.handle.net/2123/16332.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7th Edition):

Basnett, Jordan. “Characterisation of Resistance to Everolimus in Acute Lymphoblastic Leukemia .” 2016. Web. 16 Apr 2021.

Vancouver:

Basnett J. Characterisation of Resistance to Everolimus in Acute Lymphoblastic Leukemia . [Internet] [Thesis]. University of Sydney; 2016. [cited 2021 Apr 16]. Available from: http://hdl.handle.net/2123/16332.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Basnett J. Characterisation of Resistance to Everolimus in Acute Lymphoblastic Leukemia . [Thesis]. University of Sydney; 2016. Available from: http://hdl.handle.net/2123/16332

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation


Ruhr Universität Bochum

3. Abood, Assjana. Der Einfluss der Immunsuppression auf die Inzidenz von malignen Tumoren nach orthotoper Herztransplantation : ein Vergleich der mTOR-Inhibitoren Everolimus und Sirolimus.

Degree: 2014, Ruhr Universität Bochum

 Problem: Everolimus (EVL) und Sirolimus (SRL) wurden hinsichtlich der Inzidenz maligner Tumoren, Infektionen sowie im Gesamtüberleben nach Herztransplantation miteinander zu verglichen. Methode: Herztransplantationen zwischen 1989… (more)

Subjects/Keywords: Everolimus; Immunsuppression; Herztransplantation; Krebs (Medizin); Inhibitor

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Abood, A. (2014). Der Einfluss der Immunsuppression auf die Inzidenz von malignen Tumoren nach orthotoper Herztransplantation : ein Vergleich der mTOR-Inhibitoren Everolimus und Sirolimus. (Thesis). Ruhr Universität Bochum. Retrieved from http://nbn-resolving.de/urn/resolver.pl?urn=urn:nbn:de:hbz:294-43472

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16th Edition):

Abood, Assjana. “Der Einfluss der Immunsuppression auf die Inzidenz von malignen Tumoren nach orthotoper Herztransplantation : ein Vergleich der mTOR-Inhibitoren Everolimus und Sirolimus.” 2014. Thesis, Ruhr Universität Bochum. Accessed April 16, 2021. http://nbn-resolving.de/urn/resolver.pl?urn=urn:nbn:de:hbz:294-43472.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7th Edition):

Abood, Assjana. “Der Einfluss der Immunsuppression auf die Inzidenz von malignen Tumoren nach orthotoper Herztransplantation : ein Vergleich der mTOR-Inhibitoren Everolimus und Sirolimus.” 2014. Web. 16 Apr 2021.

Vancouver:

Abood A. Der Einfluss der Immunsuppression auf die Inzidenz von malignen Tumoren nach orthotoper Herztransplantation : ein Vergleich der mTOR-Inhibitoren Everolimus und Sirolimus. [Internet] [Thesis]. Ruhr Universität Bochum; 2014. [cited 2021 Apr 16]. Available from: http://nbn-resolving.de/urn/resolver.pl?urn=urn:nbn:de:hbz:294-43472.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Abood A. Der Einfluss der Immunsuppression auf die Inzidenz von malignen Tumoren nach orthotoper Herztransplantation : ein Vergleich der mTOR-Inhibitoren Everolimus und Sirolimus. [Thesis]. Ruhr Universität Bochum; 2014. Available from: http://nbn-resolving.de/urn/resolver.pl?urn=urn:nbn:de:hbz:294-43472

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

4. El Madani, Mévidette. Effets pharmacocinétique et pharmacodynamique de l’association d’everolimus et de sorafénib : l'impact des doses et des schémas d'administration sur la combinaison : Pharmacokinetics and Pharmacodynamics effects of Everolimus and Sorafenib combination : impact of doses and sequence of administration on the combination.

Degree: Docteur es, Pharmacologie clinique et évaluation des thérapeutiques, 2017, Lyon; Université Aïn-Chams (Le Caire)

Mon projet de thèse repose sur l'idée de l'optimisation du rapport bénéfice /risque (fonction d'utilité) des doses de traitements ciblés en oncologie en intégrant la… (more)

Subjects/Keywords: Pharmacocinétique; Schémas d'administration; Dose; Sorafenib; Everolimus; Pharmacokinetics; Sequence of administration; Dose; Sorafenib; Everolimus; 615

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

El Madani, M. (2017). Effets pharmacocinétique et pharmacodynamique de l’association d’everolimus et de sorafénib : l'impact des doses et des schémas d'administration sur la combinaison : Pharmacokinetics and Pharmacodynamics effects of Everolimus and Sorafenib combination : impact of doses and sequence of administration on the combination. (Doctoral Dissertation). Lyon; Université Aïn-Chams (Le Caire). Retrieved from http://www.theses.fr/2017LYSE1137

Chicago Manual of Style (16th Edition):

El Madani, Mévidette. “Effets pharmacocinétique et pharmacodynamique de l’association d’everolimus et de sorafénib : l'impact des doses et des schémas d'administration sur la combinaison : Pharmacokinetics and Pharmacodynamics effects of Everolimus and Sorafenib combination : impact of doses and sequence of administration on the combination.” 2017. Doctoral Dissertation, Lyon; Université Aïn-Chams (Le Caire). Accessed April 16, 2021. http://www.theses.fr/2017LYSE1137.

MLA Handbook (7th Edition):

El Madani, Mévidette. “Effets pharmacocinétique et pharmacodynamique de l’association d’everolimus et de sorafénib : l'impact des doses et des schémas d'administration sur la combinaison : Pharmacokinetics and Pharmacodynamics effects of Everolimus and Sorafenib combination : impact of doses and sequence of administration on the combination.” 2017. Web. 16 Apr 2021.

Vancouver:

El Madani M. Effets pharmacocinétique et pharmacodynamique de l’association d’everolimus et de sorafénib : l'impact des doses et des schémas d'administration sur la combinaison : Pharmacokinetics and Pharmacodynamics effects of Everolimus and Sorafenib combination : impact of doses and sequence of administration on the combination. [Internet] [Doctoral dissertation]. Lyon; Université Aïn-Chams (Le Caire); 2017. [cited 2021 Apr 16]. Available from: http://www.theses.fr/2017LYSE1137.

Council of Science Editors:

El Madani M. Effets pharmacocinétique et pharmacodynamique de l’association d’everolimus et de sorafénib : l'impact des doses et des schémas d'administration sur la combinaison : Pharmacokinetics and Pharmacodynamics effects of Everolimus and Sorafenib combination : impact of doses and sequence of administration on the combination. [Doctoral Dissertation]. Lyon; Université Aïn-Chams (Le Caire); 2017. Available from: http://www.theses.fr/2017LYSE1137

5. Hatem, Rana. Etude des altérations moléculaires et évaluation de nouvelles thérapies ciblées dans les cancers du sein triple-négatifs : Molecular alterations analysis and evaluation of new targeted thérapies in triple negative breast cancers.

Degree: Docteur es, Biologie moléculaire et cellulaire, 2015, Université Paris-Saclay (ComUE)

Parmi les sous-types moléculaires de cancers du sein, le cancer du sein triple-négatif (TNBC) est caractérisé par un très mauvais pronostic et ne bénéficie actuellement… (more)

Subjects/Keywords: Cancer du sein triple-Négatif; Everolimus; Vandetanib; Pdx; Triple-Negative breast cancer; Everolimus; Vandetanib; Pdx

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Hatem, R. (2015). Etude des altérations moléculaires et évaluation de nouvelles thérapies ciblées dans les cancers du sein triple-négatifs : Molecular alterations analysis and evaluation of new targeted thérapies in triple negative breast cancers. (Doctoral Dissertation). Université Paris-Saclay (ComUE). Retrieved from http://www.theses.fr/2015SACLS143

Chicago Manual of Style (16th Edition):

Hatem, Rana. “Etude des altérations moléculaires et évaluation de nouvelles thérapies ciblées dans les cancers du sein triple-négatifs : Molecular alterations analysis and evaluation of new targeted thérapies in triple negative breast cancers.” 2015. Doctoral Dissertation, Université Paris-Saclay (ComUE). Accessed April 16, 2021. http://www.theses.fr/2015SACLS143.

MLA Handbook (7th Edition):

Hatem, Rana. “Etude des altérations moléculaires et évaluation de nouvelles thérapies ciblées dans les cancers du sein triple-négatifs : Molecular alterations analysis and evaluation of new targeted thérapies in triple negative breast cancers.” 2015. Web. 16 Apr 2021.

Vancouver:

Hatem R. Etude des altérations moléculaires et évaluation de nouvelles thérapies ciblées dans les cancers du sein triple-négatifs : Molecular alterations analysis and evaluation of new targeted thérapies in triple negative breast cancers. [Internet] [Doctoral dissertation]. Université Paris-Saclay (ComUE); 2015. [cited 2021 Apr 16]. Available from: http://www.theses.fr/2015SACLS143.

Council of Science Editors:

Hatem R. Etude des altérations moléculaires et évaluation de nouvelles thérapies ciblées dans les cancers du sein triple-négatifs : Molecular alterations analysis and evaluation of new targeted thérapies in triple negative breast cancers. [Doctoral Dissertation]. Université Paris-Saclay (ComUE); 2015. Available from: http://www.theses.fr/2015SACLS143

6. Elaine Silveira. Análise da viabilidade das células H295R, linhagem de carcinoma adrenocortical tumoral humano, tratadas com diferentes drogas antitumorais.

Degree: 2014, University of São Paulo

O carcinoma adrenocortical (ACC) é um tumor maligno raro. O objetivo foi testar a ação de drogas antitumorais na linhagem H295R, em cultura 2D e… (more)

Subjects/Keywords: Carcinoma adrenocortical; Esferoides; Everolimus; Mitotano; Nilotinib; Adrenocortical carcinoma; Everolimus; Mitotane; Nilotinib; Spheroids

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Silveira, E. (2014). Análise da viabilidade das células H295R, linhagem de carcinoma adrenocortical tumoral humano, tratadas com diferentes drogas antitumorais. (Masters Thesis). University of São Paulo. Retrieved from http://www.teses.usp.br/teses/disponiveis/42/42131/tde-19022015-105918/

Chicago Manual of Style (16th Edition):

Silveira, Elaine. “Análise da viabilidade das células H295R, linhagem de carcinoma adrenocortical tumoral humano, tratadas com diferentes drogas antitumorais.” 2014. Masters Thesis, University of São Paulo. Accessed April 16, 2021. http://www.teses.usp.br/teses/disponiveis/42/42131/tde-19022015-105918/.

MLA Handbook (7th Edition):

Silveira, Elaine. “Análise da viabilidade das células H295R, linhagem de carcinoma adrenocortical tumoral humano, tratadas com diferentes drogas antitumorais.” 2014. Web. 16 Apr 2021.

Vancouver:

Silveira E. Análise da viabilidade das células H295R, linhagem de carcinoma adrenocortical tumoral humano, tratadas com diferentes drogas antitumorais. [Internet] [Masters thesis]. University of São Paulo; 2014. [cited 2021 Apr 16]. Available from: http://www.teses.usp.br/teses/disponiveis/42/42131/tde-19022015-105918/.

Council of Science Editors:

Silveira E. Análise da viabilidade das células H295R, linhagem de carcinoma adrenocortical tumoral humano, tratadas com diferentes drogas antitumorais. [Masters Thesis]. University of São Paulo; 2014. Available from: http://www.teses.usp.br/teses/disponiveis/42/42131/tde-19022015-105918/

7. Mohamed, Amerh Amira. Nouvelles molécules thérapeutiques en développement pour les tumeurs neuroendocrines d'origine gastroentéropencréatiques et hypophysaires : preuves de concept in vitro : New therapy in gastroenteropancreatic neuroendocrine cells and pituitary adenomas : Proof of concept in vitro.

Degree: Docteur es, Neurosciences, 2013, Aix Marseille Université

Les GEPNETs (tumeurs neuroendocrines gastroentéropancréatiques), représentent le deuxième cancer digestif. L’octréotide (agoniste Sst2) contrôle efficacement leurs sécrétions et plus modérément la croissance cellulaire. Au cours… (more)

Subjects/Keywords: Endocrinologie; Tumeurs neuroendocrine; Adenomes hypophysaires; Recepteur à la somatostatine; Pasireotide; Everolimus,; Endocrinology; Pituitary adenomas; Neuroendocrine tumors; Somatostatin receptor; Pasireotide; Everolimus

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Mohamed, A. A. (2013). Nouvelles molécules thérapeutiques en développement pour les tumeurs neuroendocrines d'origine gastroentéropencréatiques et hypophysaires : preuves de concept in vitro : New therapy in gastroenteropancreatic neuroendocrine cells and pituitary adenomas : Proof of concept in vitro. (Doctoral Dissertation). Aix Marseille Université. Retrieved from http://www.theses.fr/2013AIXM5049

Chicago Manual of Style (16th Edition):

Mohamed, Amerh Amira. “Nouvelles molécules thérapeutiques en développement pour les tumeurs neuroendocrines d'origine gastroentéropencréatiques et hypophysaires : preuves de concept in vitro : New therapy in gastroenteropancreatic neuroendocrine cells and pituitary adenomas : Proof of concept in vitro.” 2013. Doctoral Dissertation, Aix Marseille Université. Accessed April 16, 2021. http://www.theses.fr/2013AIXM5049.

MLA Handbook (7th Edition):

Mohamed, Amerh Amira. “Nouvelles molécules thérapeutiques en développement pour les tumeurs neuroendocrines d'origine gastroentéropencréatiques et hypophysaires : preuves de concept in vitro : New therapy in gastroenteropancreatic neuroendocrine cells and pituitary adenomas : Proof of concept in vitro.” 2013. Web. 16 Apr 2021.

Vancouver:

Mohamed AA. Nouvelles molécules thérapeutiques en développement pour les tumeurs neuroendocrines d'origine gastroentéropencréatiques et hypophysaires : preuves de concept in vitro : New therapy in gastroenteropancreatic neuroendocrine cells and pituitary adenomas : Proof of concept in vitro. [Internet] [Doctoral dissertation]. Aix Marseille Université 2013. [cited 2021 Apr 16]. Available from: http://www.theses.fr/2013AIXM5049.

Council of Science Editors:

Mohamed AA. Nouvelles molécules thérapeutiques en développement pour les tumeurs neuroendocrines d'origine gastroentéropencréatiques et hypophysaires : preuves de concept in vitro : New therapy in gastroenteropancreatic neuroendocrine cells and pituitary adenomas : Proof of concept in vitro. [Doctoral Dissertation]. Aix Marseille Université 2013. Available from: http://www.theses.fr/2013AIXM5049

8. Kezić Aleksandra. he effect of mTOR inhibitor everolimus on NF-kB activity, inflammation and outcome of kidney ischemia/reperfusion injury in mice.

Degree: PhD, Medicine, 2013, University of Belgrade

 Kidney ischemia/reperfusion (I/R) injury is clinically manifested by acute renal failure and is found in a numerous pathological conditions including kidney transplantation as one of… (more)

Subjects/Keywords: ischemia/reperfusion injury; mTOR inhibitor; everolimus; inflamamation; chemokines; NF-κB; ishemijsko/reperfuziono oštećenje; mTOR inhibitor; everolimus; inflamacija; hemokini; NF-κB

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Aleksandra, K. (2013). he effect of mTOR inhibitor everolimus on NF-kB activity, inflammation and outcome of kidney ischemia/reperfusion injury in mice. (Doctoral Dissertation). University of Belgrade. Retrieved from http://dx.doi.org/10.2298/BG20130701KEZIC ; http://eteze.bg.ac.rs/application/showtheses?thesesId=670 ; https://fedorabg.bg.ac.rs/fedora/get/o:6897/bdef:Content/get ; http://vbs.rs/scripts/cobiss?command=SEARCH&base=99999&select=ID=44670991

Chicago Manual of Style (16th Edition):

Aleksandra, Kezić. “he effect of mTOR inhibitor everolimus on NF-kB activity, inflammation and outcome of kidney ischemia/reperfusion injury in mice.” 2013. Doctoral Dissertation, University of Belgrade. Accessed April 16, 2021. http://dx.doi.org/10.2298/BG20130701KEZIC ; http://eteze.bg.ac.rs/application/showtheses?thesesId=670 ; https://fedorabg.bg.ac.rs/fedora/get/o:6897/bdef:Content/get ; http://vbs.rs/scripts/cobiss?command=SEARCH&base=99999&select=ID=44670991.

MLA Handbook (7th Edition):

Aleksandra, Kezić. “he effect of mTOR inhibitor everolimus on NF-kB activity, inflammation and outcome of kidney ischemia/reperfusion injury in mice.” 2013. Web. 16 Apr 2021.

Vancouver:

Aleksandra K. he effect of mTOR inhibitor everolimus on NF-kB activity, inflammation and outcome of kidney ischemia/reperfusion injury in mice. [Internet] [Doctoral dissertation]. University of Belgrade; 2013. [cited 2021 Apr 16]. Available from: http://dx.doi.org/10.2298/BG20130701KEZIC ; http://eteze.bg.ac.rs/application/showtheses?thesesId=670 ; https://fedorabg.bg.ac.rs/fedora/get/o:6897/bdef:Content/get ; http://vbs.rs/scripts/cobiss?command=SEARCH&base=99999&select=ID=44670991.

Council of Science Editors:

Aleksandra K. he effect of mTOR inhibitor everolimus on NF-kB activity, inflammation and outcome of kidney ischemia/reperfusion injury in mice. [Doctoral Dissertation]. University of Belgrade; 2013. Available from: http://dx.doi.org/10.2298/BG20130701KEZIC ; http://eteze.bg.ac.rs/application/showtheses?thesesId=670 ; https://fedorabg.bg.ac.rs/fedora/get/o:6897/bdef:Content/get ; http://vbs.rs/scripts/cobiss?command=SEARCH&base=99999&select=ID=44670991


Universiteit Utrecht

9. Tang, S.C. Impact of apical ABC transporters on pharmacokinetics of targeted anticancer drugs.

Degree: 2013, Universiteit Utrecht

 Tyrosine kinase inhibitors (TKIs) are small molecule inhibitors that selectively interfere with the intrinsic tyrosine kinase activity of proteins in cellular signal transduction pathways and… (more)

Subjects/Keywords: Farmacie; brain accumulation; tyrosine kinase inhibitors; everolimus; heterozygosity; oral bioavailability; carboxylesterase

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Tang, S. C. (2013). Impact of apical ABC transporters on pharmacokinetics of targeted anticancer drugs. (Doctoral Dissertation). Universiteit Utrecht. Retrieved from http://dspace.library.uu.nl:8080/handle/1874/276503

Chicago Manual of Style (16th Edition):

Tang, S C. “Impact of apical ABC transporters on pharmacokinetics of targeted anticancer drugs.” 2013. Doctoral Dissertation, Universiteit Utrecht. Accessed April 16, 2021. http://dspace.library.uu.nl:8080/handle/1874/276503.

MLA Handbook (7th Edition):

Tang, S C. “Impact of apical ABC transporters on pharmacokinetics of targeted anticancer drugs.” 2013. Web. 16 Apr 2021.

Vancouver:

Tang SC. Impact of apical ABC transporters on pharmacokinetics of targeted anticancer drugs. [Internet] [Doctoral dissertation]. Universiteit Utrecht; 2013. [cited 2021 Apr 16]. Available from: http://dspace.library.uu.nl:8080/handle/1874/276503.

Council of Science Editors:

Tang SC. Impact of apical ABC transporters on pharmacokinetics of targeted anticancer drugs. [Doctoral Dissertation]. Universiteit Utrecht; 2013. Available from: http://dspace.library.uu.nl:8080/handle/1874/276503

10. Mirantes Barbeito, Cristina. Estudio de PTEN como supresor tumoral: desarrollo de modelos animales, evaluación de terapias dirigidas e interacción con el proceso inflamatorio.

Degree: Departament de Ciències Mèdiques Bàsiques, 2015, Universitat de Lleida

 Desde su descubrimiento a finales de los 90, PTEN se ha convertido en uno de los genes supresores de tumores más importantes que se conocen.… (more)

Subjects/Keywords: PTEN; IKK; Cancer; Everolimus; Sorafenib; Biologia cel·lular; 576

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Mirantes Barbeito, C. (2015). Estudio de PTEN como supresor tumoral: desarrollo de modelos animales, evaluación de terapias dirigidas e interacción con el proceso inflamatorio. (Thesis). Universitat de Lleida. Retrieved from http://hdl.handle.net/10803/306601

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16th Edition):

Mirantes Barbeito, Cristina. “Estudio de PTEN como supresor tumoral: desarrollo de modelos animales, evaluación de terapias dirigidas e interacción con el proceso inflamatorio.” 2015. Thesis, Universitat de Lleida. Accessed April 16, 2021. http://hdl.handle.net/10803/306601.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7th Edition):

Mirantes Barbeito, Cristina. “Estudio de PTEN como supresor tumoral: desarrollo de modelos animales, evaluación de terapias dirigidas e interacción con el proceso inflamatorio.” 2015. Web. 16 Apr 2021.

Vancouver:

Mirantes Barbeito C. Estudio de PTEN como supresor tumoral: desarrollo de modelos animales, evaluación de terapias dirigidas e interacción con el proceso inflamatorio. [Internet] [Thesis]. Universitat de Lleida; 2015. [cited 2021 Apr 16]. Available from: http://hdl.handle.net/10803/306601.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Mirantes Barbeito C. Estudio de PTEN como supresor tumoral: desarrollo de modelos animales, evaluación de terapias dirigidas e interacción con el proceso inflamatorio. [Thesis]. Universitat de Lleida; 2015. Available from: http://hdl.handle.net/10803/306601

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation


Univerzitet u Beogradu

11. Kezić, Aleksandra V., 1968-. Dejstvo mTOR inhibitora everolimusa na aktivnosti NF-kB, inflamaciju i ishod ishemijsko/reperfuzionog oštećenja bubrega kod miševa.

Degree: Medicinski fakultet, 2015, Univerzitet u Beogradu

Nefrologija i imunofarmakologija / Nephrology and Immunopharmacology

Ishemijsko-reperfuziono (I/R) oštećenje bubrega klinički se manifestuje akutnom bubrežnom insuficijencijom. Javlja se u mnogim patološkim stanjima meĎu kojima… (more)

Subjects/Keywords: ischemia/reperfusion injury; mTOR inhibitor; everolimus; inflamamation; chemokines; NF-κB

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Kezić, Aleksandra V., 1. (2015). Dejstvo mTOR inhibitora everolimusa na aktivnosti NF-kB, inflamaciju i ishod ishemijsko/reperfuzionog oštećenja bubrega kod miševa. (Thesis). Univerzitet u Beogradu. Retrieved from https://fedorabg.bg.ac.rs/fedora/get/o:6897/bdef:Content/get

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16th Edition):

Kezić, Aleksandra V., 1968-. “Dejstvo mTOR inhibitora everolimusa na aktivnosti NF-kB, inflamaciju i ishod ishemijsko/reperfuzionog oštećenja bubrega kod miševa.” 2015. Thesis, Univerzitet u Beogradu. Accessed April 16, 2021. https://fedorabg.bg.ac.rs/fedora/get/o:6897/bdef:Content/get.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7th Edition):

Kezić, Aleksandra V., 1968-. “Dejstvo mTOR inhibitora everolimusa na aktivnosti NF-kB, inflamaciju i ishod ishemijsko/reperfuzionog oštećenja bubrega kod miševa.” 2015. Web. 16 Apr 2021.

Vancouver:

Kezić, Aleksandra V. 1. Dejstvo mTOR inhibitora everolimusa na aktivnosti NF-kB, inflamaciju i ishod ishemijsko/reperfuzionog oštećenja bubrega kod miševa. [Internet] [Thesis]. Univerzitet u Beogradu; 2015. [cited 2021 Apr 16]. Available from: https://fedorabg.bg.ac.rs/fedora/get/o:6897/bdef:Content/get.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Kezić, Aleksandra V. 1. Dejstvo mTOR inhibitora everolimusa na aktivnosti NF-kB, inflamaciju i ishod ishemijsko/reperfuzionog oštećenja bubrega kod miševa. [Thesis]. Univerzitet u Beogradu; 2015. Available from: https://fedorabg.bg.ac.rs/fedora/get/o:6897/bdef:Content/get

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation


University of Cincinnati

12. Moorthy, Ganesh. Clinical Pharmacokinetics of the Novel Combination of BEZ235, PI3K/mTOR Inhibitor, and Everolimus, mTOR Inhibitor: Phase I Clinical Studies and Non-clinical Mechanistic Assessment.

Degree: PhD, Pharmacy: Pharmaceutical Sciences/Biopharmaceutics, 2015, University of Cincinnati

 Dysregulation of PI3K/Akt/mTOR pathway has been implicated in tumorigenesis and malignancy in numerous solid tumors. Everolimus is a potent allosteric inhibitor of mTORC1, and has… (more)

Subjects/Keywords: Pharmaceuticals; pharmacokinetics; Phase I; PBPK; DDI; BEZ235; Everolimus

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Moorthy, G. (2015). Clinical Pharmacokinetics of the Novel Combination of BEZ235, PI3K/mTOR Inhibitor, and Everolimus, mTOR Inhibitor: Phase I Clinical Studies and Non-clinical Mechanistic Assessment. (Doctoral Dissertation). University of Cincinnati. Retrieved from http://rave.ohiolink.edu/etdc/view?acc_num=ucin1439296033

Chicago Manual of Style (16th Edition):

Moorthy, Ganesh. “Clinical Pharmacokinetics of the Novel Combination of BEZ235, PI3K/mTOR Inhibitor, and Everolimus, mTOR Inhibitor: Phase I Clinical Studies and Non-clinical Mechanistic Assessment.” 2015. Doctoral Dissertation, University of Cincinnati. Accessed April 16, 2021. http://rave.ohiolink.edu/etdc/view?acc_num=ucin1439296033.

MLA Handbook (7th Edition):

Moorthy, Ganesh. “Clinical Pharmacokinetics of the Novel Combination of BEZ235, PI3K/mTOR Inhibitor, and Everolimus, mTOR Inhibitor: Phase I Clinical Studies and Non-clinical Mechanistic Assessment.” 2015. Web. 16 Apr 2021.

Vancouver:

Moorthy G. Clinical Pharmacokinetics of the Novel Combination of BEZ235, PI3K/mTOR Inhibitor, and Everolimus, mTOR Inhibitor: Phase I Clinical Studies and Non-clinical Mechanistic Assessment. [Internet] [Doctoral dissertation]. University of Cincinnati; 2015. [cited 2021 Apr 16]. Available from: http://rave.ohiolink.edu/etdc/view?acc_num=ucin1439296033.

Council of Science Editors:

Moorthy G. Clinical Pharmacokinetics of the Novel Combination of BEZ235, PI3K/mTOR Inhibitor, and Everolimus, mTOR Inhibitor: Phase I Clinical Studies and Non-clinical Mechanistic Assessment. [Doctoral Dissertation]. University of Cincinnati; 2015. Available from: http://rave.ohiolink.edu/etdc/view?acc_num=ucin1439296033

13. Kremer, Hélène. Dysfonctions vasculaire et musculaire, aiguë et chronique. Quelle place pour la modulation pharmacologique du stress oxydant ? : Vascular and muscular dysfunctions in acute and chronic injury models. What is the place for a pharmacological modulation of oxidative stress?.

Degree: Docteur es, Biologie des organismes : développement et physiologie, 2012, Université de Strasbourg

Le but de notre travail était l’étude des dysfonctions artérielle et musculaire dans des modèles d’agression aiguë et chronique puis l’évaluation de l’effet de la… (more)

Subjects/Keywords: Dysfonction vasculaire; Dysfonction musculaire; Choc endotoxinique; Albumine; Ciclosporine; Everolimus; Polyphénols; Stress oxydant; Vascular dysfunction; Muscular dysfunction; Endotoxinic shock; Albumin; Ciclosporine; Everolimus; Polyphenols; Oxydative stress; 616.13; 616.7; 615

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Kremer, H. (2012). Dysfonctions vasculaire et musculaire, aiguë et chronique. Quelle place pour la modulation pharmacologique du stress oxydant ? : Vascular and muscular dysfunctions in acute and chronic injury models. What is the place for a pharmacological modulation of oxidative stress?. (Doctoral Dissertation). Université de Strasbourg. Retrieved from http://www.theses.fr/2012STRAJ135

Chicago Manual of Style (16th Edition):

Kremer, Hélène. “Dysfonctions vasculaire et musculaire, aiguë et chronique. Quelle place pour la modulation pharmacologique du stress oxydant ? : Vascular and muscular dysfunctions in acute and chronic injury models. What is the place for a pharmacological modulation of oxidative stress?.” 2012. Doctoral Dissertation, Université de Strasbourg. Accessed April 16, 2021. http://www.theses.fr/2012STRAJ135.

MLA Handbook (7th Edition):

Kremer, Hélène. “Dysfonctions vasculaire et musculaire, aiguë et chronique. Quelle place pour la modulation pharmacologique du stress oxydant ? : Vascular and muscular dysfunctions in acute and chronic injury models. What is the place for a pharmacological modulation of oxidative stress?.” 2012. Web. 16 Apr 2021.

Vancouver:

Kremer H. Dysfonctions vasculaire et musculaire, aiguë et chronique. Quelle place pour la modulation pharmacologique du stress oxydant ? : Vascular and muscular dysfunctions in acute and chronic injury models. What is the place for a pharmacological modulation of oxidative stress?. [Internet] [Doctoral dissertation]. Université de Strasbourg; 2012. [cited 2021 Apr 16]. Available from: http://www.theses.fr/2012STRAJ135.

Council of Science Editors:

Kremer H. Dysfonctions vasculaire et musculaire, aiguë et chronique. Quelle place pour la modulation pharmacologique du stress oxydant ? : Vascular and muscular dysfunctions in acute and chronic injury models. What is the place for a pharmacological modulation of oxidative stress?. [Doctoral Dissertation]. Université de Strasbourg; 2012. Available from: http://www.theses.fr/2012STRAJ135

14. Graillon, Thomas. Etudes des voies somatostatinergiques et Pi3Kinase-Akt-mTOR dans les tumeurs intra-crâniennes (Adénomes hypophysaires, Méningiomes, Chordomes) : Pi3Kinase-Akt-mTOR and somatostatin pathways study in intra-cranial tumors (pituitary adenomas, meningiomas, and chordomas).

Degree: Docteur es, Neurosciences, 2014, Aix Marseille Université

1. Adénomes hypophysaires somatotropes : Elaboration d'un modèle in vitro et in vivo d'études du récepteur SST2 et des voies de signalisation somatostatinergiques.Afin de préciser… (more)

Subjects/Keywords: Méningiomes; Therapie; Chordomes; Mtor; Somatostatine; Octreotide; Everolimus; Akt; Adénomes hypophysaires somatotropes; Meningiomas; Therapy; Chordomas; Mtor; Somatostatin; Octreotide; Everolimus; Akt; Somatotroph pituitary adenomas

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Graillon, T. (2014). Etudes des voies somatostatinergiques et Pi3Kinase-Akt-mTOR dans les tumeurs intra-crâniennes (Adénomes hypophysaires, Méningiomes, Chordomes) : Pi3Kinase-Akt-mTOR and somatostatin pathways study in intra-cranial tumors (pituitary adenomas, meningiomas, and chordomas). (Doctoral Dissertation). Aix Marseille Université. Retrieved from http://www.theses.fr/2014AIXM5053

Chicago Manual of Style (16th Edition):

Graillon, Thomas. “Etudes des voies somatostatinergiques et Pi3Kinase-Akt-mTOR dans les tumeurs intra-crâniennes (Adénomes hypophysaires, Méningiomes, Chordomes) : Pi3Kinase-Akt-mTOR and somatostatin pathways study in intra-cranial tumors (pituitary adenomas, meningiomas, and chordomas).” 2014. Doctoral Dissertation, Aix Marseille Université. Accessed April 16, 2021. http://www.theses.fr/2014AIXM5053.

MLA Handbook (7th Edition):

Graillon, Thomas. “Etudes des voies somatostatinergiques et Pi3Kinase-Akt-mTOR dans les tumeurs intra-crâniennes (Adénomes hypophysaires, Méningiomes, Chordomes) : Pi3Kinase-Akt-mTOR and somatostatin pathways study in intra-cranial tumors (pituitary adenomas, meningiomas, and chordomas).” 2014. Web. 16 Apr 2021.

Vancouver:

Graillon T. Etudes des voies somatostatinergiques et Pi3Kinase-Akt-mTOR dans les tumeurs intra-crâniennes (Adénomes hypophysaires, Méningiomes, Chordomes) : Pi3Kinase-Akt-mTOR and somatostatin pathways study in intra-cranial tumors (pituitary adenomas, meningiomas, and chordomas). [Internet] [Doctoral dissertation]. Aix Marseille Université 2014. [cited 2021 Apr 16]. Available from: http://www.theses.fr/2014AIXM5053.

Council of Science Editors:

Graillon T. Etudes des voies somatostatinergiques et Pi3Kinase-Akt-mTOR dans les tumeurs intra-crâniennes (Adénomes hypophysaires, Méningiomes, Chordomes) : Pi3Kinase-Akt-mTOR and somatostatin pathways study in intra-cranial tumors (pituitary adenomas, meningiomas, and chordomas). [Doctoral Dissertation]. Aix Marseille Université 2014. Available from: http://www.theses.fr/2014AIXM5053


Anna University

15. Syamantak Majumder. Study of the role of hepatic stellate cells in liver fibrosis;.

Degree: 2013, Anna University

In chronic liver injury, activated hepatic stellate cells (HSC) are the major source of collagens that facilitate liver fibrosis. Drugs and stem cells targeting patho-physiology… (more)

Subjects/Keywords: Hepatic stellate cells; stem cell; liver fibrosis; sunitinib; everolimus; mTOR; endothelial cells

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Majumder, S. (2013). Study of the role of hepatic stellate cells in liver fibrosis;. (Thesis). Anna University. Retrieved from http://shodhganga.inflibnet.ac.in/handle/10603/11527

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16th Edition):

Majumder, Syamantak. “Study of the role of hepatic stellate cells in liver fibrosis;.” 2013. Thesis, Anna University. Accessed April 16, 2021. http://shodhganga.inflibnet.ac.in/handle/10603/11527.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7th Edition):

Majumder, Syamantak. “Study of the role of hepatic stellate cells in liver fibrosis;.” 2013. Web. 16 Apr 2021.

Vancouver:

Majumder S. Study of the role of hepatic stellate cells in liver fibrosis;. [Internet] [Thesis]. Anna University; 2013. [cited 2021 Apr 16]. Available from: http://shodhganga.inflibnet.ac.in/handle/10603/11527.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Majumder S. Study of the role of hepatic stellate cells in liver fibrosis;. [Thesis]. Anna University; 2013. Available from: http://shodhganga.inflibnet.ac.in/handle/10603/11527

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation


Freie Universität Berlin

16. Eucker, Jan. Optimizing the treatment of metastatic breast cancer with special consideration of the Pi3K/Akt/mTOR pathway.

Degree: 2013, Freie Universität Berlin

 The work is focused on optimizing the treatment of metastatic breast cancer in vitro as well as in vivo. Especially the treatment of breast cancer… (more)

Subjects/Keywords: MTOR; metastatic breast cancer; everolimus; 600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Eucker, J. (2013). Optimizing the treatment of metastatic breast cancer with special consideration of the Pi3K/Akt/mTOR pathway. (Thesis). Freie Universität Berlin. Retrieved from http://dx.doi.org/10.17169/refubium-12117

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16th Edition):

Eucker, Jan. “Optimizing the treatment of metastatic breast cancer with special consideration of the Pi3K/Akt/mTOR pathway.” 2013. Thesis, Freie Universität Berlin. Accessed April 16, 2021. http://dx.doi.org/10.17169/refubium-12117.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7th Edition):

Eucker, Jan. “Optimizing the treatment of metastatic breast cancer with special consideration of the Pi3K/Akt/mTOR pathway.” 2013. Web. 16 Apr 2021.

Vancouver:

Eucker J. Optimizing the treatment of metastatic breast cancer with special consideration of the Pi3K/Akt/mTOR pathway. [Internet] [Thesis]. Freie Universität Berlin; 2013. [cited 2021 Apr 16]. Available from: http://dx.doi.org/10.17169/refubium-12117.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Eucker J. Optimizing the treatment of metastatic breast cancer with special consideration of the Pi3K/Akt/mTOR pathway. [Thesis]. Freie Universität Berlin; 2013. Available from: http://dx.doi.org/10.17169/refubium-12117

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation


Freie Universität Berlin

17. Lehmkuhl, Hans Brendan. efficacy in prevention of rejection and impact on kidney function.

Degree: 2010, Freie Universität Berlin

 The aim of the study was to determine the clinical value of MMF and the value of EC-MPA, furthermore, the evaluation of efficacy and safety… (more)

Subjects/Keywords: heart transplantation; everolimus; kidney; failure; immunossuppression; 600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Lehmkuhl, H. B. (2010). efficacy in prevention of rejection and impact on kidney function. (Thesis). Freie Universität Berlin. Retrieved from https://refubium.fu-berlin.de/handle/fub188/12659

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16th Edition):

Lehmkuhl, Hans Brendan. “efficacy in prevention of rejection and impact on kidney function.” 2010. Thesis, Freie Universität Berlin. Accessed April 16, 2021. https://refubium.fu-berlin.de/handle/fub188/12659.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7th Edition):

Lehmkuhl, Hans Brendan. “efficacy in prevention of rejection and impact on kidney function.” 2010. Web. 16 Apr 2021.

Vancouver:

Lehmkuhl HB. efficacy in prevention of rejection and impact on kidney function. [Internet] [Thesis]. Freie Universität Berlin; 2010. [cited 2021 Apr 16]. Available from: https://refubium.fu-berlin.de/handle/fub188/12659.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Lehmkuhl HB. efficacy in prevention of rejection and impact on kidney function. [Thesis]. Freie Universität Berlin; 2010. Available from: https://refubium.fu-berlin.de/handle/fub188/12659

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation


Freie Universität Berlin

18. Wu, Haibo. Immunsuppression mit Everolimus bei Kindern nach Herztransplantation.

Degree: 2014, Freie Universität Berlin

 Derzeit besteht keine oder eine nur geringe Erfahrung mit dem Gebrauch von Everolimus als de-novo Therapie zur Immunsuppression bei Kinderherztransplantationen. Dies ist die erste und… (more)

Subjects/Keywords: Everolimus; immunosuppression; paediatrics; heart transplantation; 600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Wu, H. (2014). Immunsuppression mit Everolimus bei Kindern nach Herztransplantation. (Thesis). Freie Universität Berlin. Retrieved from http://dx.doi.org/10.17169/refubium-6708

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16th Edition):

Wu, Haibo. “Immunsuppression mit Everolimus bei Kindern nach Herztransplantation.” 2014. Thesis, Freie Universität Berlin. Accessed April 16, 2021. http://dx.doi.org/10.17169/refubium-6708.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7th Edition):

Wu, Haibo. “Immunsuppression mit Everolimus bei Kindern nach Herztransplantation.” 2014. Web. 16 Apr 2021.

Vancouver:

Wu H. Immunsuppression mit Everolimus bei Kindern nach Herztransplantation. [Internet] [Thesis]. Freie Universität Berlin; 2014. [cited 2021 Apr 16]. Available from: http://dx.doi.org/10.17169/refubium-6708.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Wu H. Immunsuppression mit Everolimus bei Kindern nach Herztransplantation. [Thesis]. Freie Universität Berlin; 2014. Available from: http://dx.doi.org/10.17169/refubium-6708

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

19. Andressa Duarte. A participação da via fosfatidilinositol3-quinase (PI3K)/mTOR no carcinoma epidermoide oral.

Degree: 2018, University of São Paulo

O carcinoma epidermoide oral (CEO) possui alta incidência no Brasil, correspondendo a aproximadamente 95% das neoplasias malignas orais. A biologia molecular do carcinoma de cabeça… (more)

Subjects/Keywords: AKT; Câncer; Everolimus; mTOR; PI3K; Rapamicina; Torin1; Via de sinalização; Não informado

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Duarte, A. (2018). A participação da via fosfatidilinositol3-quinase (PI3K)/mTOR no carcinoma epidermoide oral. (Doctoral Dissertation). University of São Paulo. Retrieved from http://www.teses.usp.br/teses/disponiveis/17/17143/tde-20072018-092758/

Chicago Manual of Style (16th Edition):

Duarte, Andressa. “A participação da via fosfatidilinositol3-quinase (PI3K)/mTOR no carcinoma epidermoide oral.” 2018. Doctoral Dissertation, University of São Paulo. Accessed April 16, 2021. http://www.teses.usp.br/teses/disponiveis/17/17143/tde-20072018-092758/.

MLA Handbook (7th Edition):

Duarte, Andressa. “A participação da via fosfatidilinositol3-quinase (PI3K)/mTOR no carcinoma epidermoide oral.” 2018. Web. 16 Apr 2021.

Vancouver:

Duarte A. A participação da via fosfatidilinositol3-quinase (PI3K)/mTOR no carcinoma epidermoide oral. [Internet] [Doctoral dissertation]. University of São Paulo; 2018. [cited 2021 Apr 16]. Available from: http://www.teses.usp.br/teses/disponiveis/17/17143/tde-20072018-092758/.

Council of Science Editors:

Duarte A. A participação da via fosfatidilinositol3-quinase (PI3K)/mTOR no carcinoma epidermoide oral. [Doctoral Dissertation]. University of São Paulo; 2018. Available from: http://www.teses.usp.br/teses/disponiveis/17/17143/tde-20072018-092758/


Université Paris-Sud – Paris XI

20. Chu, Céline. Etude de l’effet sur la P‐glycoprotéine (ABCB1) de deux médicaments dirigés contre le récepteur de facteur de croissance épithélial (EGFR), le cétuximab et le lapatinib et conséquence sur la pharmacocinétique et l’efficacité anti‐tumorale de médicaments substrats de ABCB1 : Effect of two epidermal growth factor receptor (EGFR) targeting drugs, cetuximab and lapatinib, on P-glycoprotein (ABCB1) and their influence on pharmacokinetics and antitumoral efficiency of ABCB1 substrate drugs.

Degree: Docteur es, Pharmacologie experimentale et clinique, 2013, Université Paris-Sud – Paris XI

La P-glycoprotéine (P-gp) est une protéine transmembranaire de la famille des ATP binding cassette transporteurs. Elle est impliquée dans l’efflux du milieu intracellulaire vers le… (more)

Subjects/Keywords: Evérolimus; Lapatinib; Cétuximab; Irinotécan; P-glycoprotéine; Xénogreffe de cancer colorectal; Everolimus; Lapatinib; Cetuximab; Irinotecan; P-glycoprotein; Colorectal carcinoma xenograft

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Chu, C. (2013). Etude de l’effet sur la P‐glycoprotéine (ABCB1) de deux médicaments dirigés contre le récepteur de facteur de croissance épithélial (EGFR), le cétuximab et le lapatinib et conséquence sur la pharmacocinétique et l’efficacité anti‐tumorale de médicaments substrats de ABCB1 : Effect of two epidermal growth factor receptor (EGFR) targeting drugs, cetuximab and lapatinib, on P-glycoprotein (ABCB1) and their influence on pharmacokinetics and antitumoral efficiency of ABCB1 substrate drugs. (Doctoral Dissertation). Université Paris-Sud – Paris XI. Retrieved from http://www.theses.fr/2013PA114806

Chicago Manual of Style (16th Edition):

Chu, Céline. “Etude de l’effet sur la P‐glycoprotéine (ABCB1) de deux médicaments dirigés contre le récepteur de facteur de croissance épithélial (EGFR), le cétuximab et le lapatinib et conséquence sur la pharmacocinétique et l’efficacité anti‐tumorale de médicaments substrats de ABCB1 : Effect of two epidermal growth factor receptor (EGFR) targeting drugs, cetuximab and lapatinib, on P-glycoprotein (ABCB1) and their influence on pharmacokinetics and antitumoral efficiency of ABCB1 substrate drugs.” 2013. Doctoral Dissertation, Université Paris-Sud – Paris XI. Accessed April 16, 2021. http://www.theses.fr/2013PA114806.

MLA Handbook (7th Edition):

Chu, Céline. “Etude de l’effet sur la P‐glycoprotéine (ABCB1) de deux médicaments dirigés contre le récepteur de facteur de croissance épithélial (EGFR), le cétuximab et le lapatinib et conséquence sur la pharmacocinétique et l’efficacité anti‐tumorale de médicaments substrats de ABCB1 : Effect of two epidermal growth factor receptor (EGFR) targeting drugs, cetuximab and lapatinib, on P-glycoprotein (ABCB1) and their influence on pharmacokinetics and antitumoral efficiency of ABCB1 substrate drugs.” 2013. Web. 16 Apr 2021.

Vancouver:

Chu C. Etude de l’effet sur la P‐glycoprotéine (ABCB1) de deux médicaments dirigés contre le récepteur de facteur de croissance épithélial (EGFR), le cétuximab et le lapatinib et conséquence sur la pharmacocinétique et l’efficacité anti‐tumorale de médicaments substrats de ABCB1 : Effect of two epidermal growth factor receptor (EGFR) targeting drugs, cetuximab and lapatinib, on P-glycoprotein (ABCB1) and their influence on pharmacokinetics and antitumoral efficiency of ABCB1 substrate drugs. [Internet] [Doctoral dissertation]. Université Paris-Sud – Paris XI; 2013. [cited 2021 Apr 16]. Available from: http://www.theses.fr/2013PA114806.

Council of Science Editors:

Chu C. Etude de l’effet sur la P‐glycoprotéine (ABCB1) de deux médicaments dirigés contre le récepteur de facteur de croissance épithélial (EGFR), le cétuximab et le lapatinib et conséquence sur la pharmacocinétique et l’efficacité anti‐tumorale de médicaments substrats de ABCB1 : Effect of two epidermal growth factor receptor (EGFR) targeting drugs, cetuximab and lapatinib, on P-glycoprotein (ABCB1) and their influence on pharmacokinetics and antitumoral efficiency of ABCB1 substrate drugs. [Doctoral Dissertation]. Université Paris-Sud – Paris XI; 2013. Available from: http://www.theses.fr/2013PA114806


Freie Universität Berlin

21. Lehnert, Martin. Effect of immunosuppressive agents on human B lymphocyte functions.

Degree: 2013, Freie Universität Berlin

 Kidney transplantation is an established therapy for patients with end-stage renal disease. Today T-cell mediated allograft rejection can be treated well. However humoral allograft rejection… (more)

Subjects/Keywords: B-lymphocytes; everolimus; humoral rejection; MPA; sotrastaurin; 600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Lehnert, M. (2013). Effect of immunosuppressive agents on human B lymphocyte functions. (Thesis). Freie Universität Berlin. Retrieved from http://dx.doi.org/10.17169/refubium-4650

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16th Edition):

Lehnert, Martin. “Effect of immunosuppressive agents on human B lymphocyte functions.” 2013. Thesis, Freie Universität Berlin. Accessed April 16, 2021. http://dx.doi.org/10.17169/refubium-4650.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7th Edition):

Lehnert, Martin. “Effect of immunosuppressive agents on human B lymphocyte functions.” 2013. Web. 16 Apr 2021.

Vancouver:

Lehnert M. Effect of immunosuppressive agents on human B lymphocyte functions. [Internet] [Thesis]. Freie Universität Berlin; 2013. [cited 2021 Apr 16]. Available from: http://dx.doi.org/10.17169/refubium-4650.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Lehnert M. Effect of immunosuppressive agents on human B lymphocyte functions. [Thesis]. Freie Universität Berlin; 2013. Available from: http://dx.doi.org/10.17169/refubium-4650

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation


Freie Universität Berlin

22. Otasevic-Wieschalla, Ljiljana. Neue Medikamente für die Vermeidung von experimenteller Hornhauttransplantatabstoßung.

Degree: 2014, Freie Universität Berlin

 Hintergrund: Immunmediierte Abstoßungsreaktionen sind Hauptursache des Transplantat-versagens nach perforierender Keratoplastik und stellen weiterhin eine Herausforderung dar. Zielsetzung: Wir untersuchten die Effekte eines selektiven Glucocorticoidrezeptoragonisten (SEGRA)… (more)

Subjects/Keywords: experimental keratoplasty; graft survival; topical therapy; SEGRA; everolimus; spironolactone; 600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Otasevic-Wieschalla, L. (2014). Neue Medikamente für die Vermeidung von experimenteller Hornhauttransplantatabstoßung. (Thesis). Freie Universität Berlin. Retrieved from http://dx.doi.org/10.17169/refubium-9901

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16th Edition):

Otasevic-Wieschalla, Ljiljana. “Neue Medikamente für die Vermeidung von experimenteller Hornhauttransplantatabstoßung.” 2014. Thesis, Freie Universität Berlin. Accessed April 16, 2021. http://dx.doi.org/10.17169/refubium-9901.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7th Edition):

Otasevic-Wieschalla, Ljiljana. “Neue Medikamente für die Vermeidung von experimenteller Hornhauttransplantatabstoßung.” 2014. Web. 16 Apr 2021.

Vancouver:

Otasevic-Wieschalla L. Neue Medikamente für die Vermeidung von experimenteller Hornhauttransplantatabstoßung. [Internet] [Thesis]. Freie Universität Berlin; 2014. [cited 2021 Apr 16]. Available from: http://dx.doi.org/10.17169/refubium-9901.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Otasevic-Wieschalla L. Neue Medikamente für die Vermeidung von experimenteller Hornhauttransplantatabstoßung. [Thesis]. Freie Universität Berlin; 2014. Available from: http://dx.doi.org/10.17169/refubium-9901

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation


Freie Universität Berlin

23. Beth, Katrin. Pharmacodynamic monitoring after conversion from calcineurin inhibitors to everolimus in stable renal-transplant recipients.

Degree: 2011, Freie Universität Berlin

 Therapy with calcineurin-Inhibitors (CNI) in combination with mycophenolic acid (MPA) and methylprednisolon is worldwide standard after kidney transplantation. One main side effect of CNI is… (more)

Subjects/Keywords: cyclosporine; calcineurin inhibitor; everolimus; tacrolimus; pharmacodynamic monitoring; 600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Beth, K. (2011). Pharmacodynamic monitoring after conversion from calcineurin inhibitors to everolimus in stable renal-transplant recipients. (Thesis). Freie Universität Berlin. Retrieved from https://refubium.fu-berlin.de/handle/fub188/12729

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16th Edition):

Beth, Katrin. “Pharmacodynamic monitoring after conversion from calcineurin inhibitors to everolimus in stable renal-transplant recipients.” 2011. Thesis, Freie Universität Berlin. Accessed April 16, 2021. https://refubium.fu-berlin.de/handle/fub188/12729.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7th Edition):

Beth, Katrin. “Pharmacodynamic monitoring after conversion from calcineurin inhibitors to everolimus in stable renal-transplant recipients.” 2011. Web. 16 Apr 2021.

Vancouver:

Beth K. Pharmacodynamic monitoring after conversion from calcineurin inhibitors to everolimus in stable renal-transplant recipients. [Internet] [Thesis]. Freie Universität Berlin; 2011. [cited 2021 Apr 16]. Available from: https://refubium.fu-berlin.de/handle/fub188/12729.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Beth K. Pharmacodynamic monitoring after conversion from calcineurin inhibitors to everolimus in stable renal-transplant recipients. [Thesis]. Freie Universität Berlin; 2011. Available from: https://refubium.fu-berlin.de/handle/fub188/12729

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

24. Pouget, Mélanie. Intervention biologique dans les cancers hormono-dépendants. : Biological intervention on hormone dependant cancers.

Degree: Docteur es, Sciences de la vie et de la sante, 2016, Clermont-Ferrand 1

 Les cancers hormono-dépendants : le cancer du sein et de la prostate, sont les plusfréquents respectivement chez la femme et chez l’homme. Ces cancers représentent… (more)

Subjects/Keywords: Cancer de la prostate; Curcumine.; Évérolimus,; Cancer du sein; Breast cancer,; Curcumin.; Everolimus,; Prostate cancer,; 610

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Pouget, M. (2016). Intervention biologique dans les cancers hormono-dépendants. : Biological intervention on hormone dependant cancers. (Doctoral Dissertation). Clermont-Ferrand 1. Retrieved from http://www.theses.fr/2016CLF1MM14

Chicago Manual of Style (16th Edition):

Pouget, Mélanie. “Intervention biologique dans les cancers hormono-dépendants. : Biological intervention on hormone dependant cancers.” 2016. Doctoral Dissertation, Clermont-Ferrand 1. Accessed April 16, 2021. http://www.theses.fr/2016CLF1MM14.

MLA Handbook (7th Edition):

Pouget, Mélanie. “Intervention biologique dans les cancers hormono-dépendants. : Biological intervention on hormone dependant cancers.” 2016. Web. 16 Apr 2021.

Vancouver:

Pouget M. Intervention biologique dans les cancers hormono-dépendants. : Biological intervention on hormone dependant cancers. [Internet] [Doctoral dissertation]. Clermont-Ferrand 1; 2016. [cited 2021 Apr 16]. Available from: http://www.theses.fr/2016CLF1MM14.

Council of Science Editors:

Pouget M. Intervention biologique dans les cancers hormono-dépendants. : Biological intervention on hormone dependant cancers. [Doctoral Dissertation]. Clermont-Ferrand 1; 2016. Available from: http://www.theses.fr/2016CLF1MM14


Freie Universität Berlin

25. Haug, Marcel. Influence of immunosuppression on the progression of renal failure in the 5/6 renal ablation rat model.

Degree: 2015, Freie Universität Berlin

Everolimus is used as part of immunosuppressive therapy in renal and heart transplanted patients due to its high immunosuppressive potential and lack of nephrotoxicity. Recent… (more)

Subjects/Keywords: cyclosporin; everolimus; renal dysfunction; renal ablation; rat; 600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Haug, M. (2015). Influence of immunosuppression on the progression of renal failure in the 5/6 renal ablation rat model. (Thesis). Freie Universität Berlin. Retrieved from http://dx.doi.org/10.17169/refubium-8985

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16th Edition):

Haug, Marcel. “Influence of immunosuppression on the progression of renal failure in the 5/6 renal ablation rat model.” 2015. Thesis, Freie Universität Berlin. Accessed April 16, 2021. http://dx.doi.org/10.17169/refubium-8985.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7th Edition):

Haug, Marcel. “Influence of immunosuppression on the progression of renal failure in the 5/6 renal ablation rat model.” 2015. Web. 16 Apr 2021.

Vancouver:

Haug M. Influence of immunosuppression on the progression of renal failure in the 5/6 renal ablation rat model. [Internet] [Thesis]. Freie Universität Berlin; 2015. [cited 2021 Apr 16]. Available from: http://dx.doi.org/10.17169/refubium-8985.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Haug M. Influence of immunosuppression on the progression of renal failure in the 5/6 renal ablation rat model. [Thesis]. Freie Universität Berlin; 2015. Available from: http://dx.doi.org/10.17169/refubium-8985

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation


Freie Universität Berlin

26. Kratzsch, Tobias. preclinical and experimental studies proving the effectiveness of new tyrosine kinase inhibitors as well as epigenetically active substances in different glioblastoma mouse models.

Degree: 2015, Freie Universität Berlin

 In recent years, the targeted therapy of tumor diseases obtained increasingly importance in modern oncology and showed very good treatment effects in many different tumor… (more)

Subjects/Keywords: glioblastoma; glioblastoma xenografts; targeted therapy; everolimus; axitinib; 5-azacitidine; 600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Kratzsch, T. (2015). preclinical and experimental studies proving the effectiveness of new tyrosine kinase inhibitors as well as epigenetically active substances in different glioblastoma mouse models. (Thesis). Freie Universität Berlin. Retrieved from http://dx.doi.org/10.17169/refubium-4465

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16th Edition):

Kratzsch, Tobias. “preclinical and experimental studies proving the effectiveness of new tyrosine kinase inhibitors as well as epigenetically active substances in different glioblastoma mouse models.” 2015. Thesis, Freie Universität Berlin. Accessed April 16, 2021. http://dx.doi.org/10.17169/refubium-4465.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7th Edition):

Kratzsch, Tobias. “preclinical and experimental studies proving the effectiveness of new tyrosine kinase inhibitors as well as epigenetically active substances in different glioblastoma mouse models.” 2015. Web. 16 Apr 2021.

Vancouver:

Kratzsch T. preclinical and experimental studies proving the effectiveness of new tyrosine kinase inhibitors as well as epigenetically active substances in different glioblastoma mouse models. [Internet] [Thesis]. Freie Universität Berlin; 2015. [cited 2021 Apr 16]. Available from: http://dx.doi.org/10.17169/refubium-4465.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Kratzsch T. preclinical and experimental studies proving the effectiveness of new tyrosine kinase inhibitors as well as epigenetically active substances in different glioblastoma mouse models. [Thesis]. Freie Universität Berlin; 2015. Available from: http://dx.doi.org/10.17169/refubium-4465

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

27. Kruger, D.T. Endocrine responsiveness in estrogen receptor-positive breast cancer: Search for biomarkers associated with treatment failure.

Degree: 2020, NARCIS

Subjects/Keywords: breast cancer; endocrine resistance; tamoxifen; everolimus; PI3K pathway

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Kruger, D. T. (2020). Endocrine responsiveness in estrogen receptor-positive breast cancer: Search for biomarkers associated with treatment failure. (Doctoral Dissertation). NARCIS. Retrieved from https://research.vumc.nl/en/publications/88343427-dce7-4622-b8ae-82b6449bbcc1 ; urn:nbn:nl:ui:31-88343427-dce7-4622-b8ae-82b6449bbcc1 ; 88343427-dce7-4622-b8ae-82b6449bbcc1 ; urn:nbn:nl:ui:31-88343427-dce7-4622-b8ae-82b6449bbcc1 ; https://research.vumc.nl/en/publications/88343427-dce7-4622-b8ae-82b6449bbcc1

Chicago Manual of Style (16th Edition):

Kruger, D T. “Endocrine responsiveness in estrogen receptor-positive breast cancer: Search for biomarkers associated with treatment failure.” 2020. Doctoral Dissertation, NARCIS. Accessed April 16, 2021. https://research.vumc.nl/en/publications/88343427-dce7-4622-b8ae-82b6449bbcc1 ; urn:nbn:nl:ui:31-88343427-dce7-4622-b8ae-82b6449bbcc1 ; 88343427-dce7-4622-b8ae-82b6449bbcc1 ; urn:nbn:nl:ui:31-88343427-dce7-4622-b8ae-82b6449bbcc1 ; https://research.vumc.nl/en/publications/88343427-dce7-4622-b8ae-82b6449bbcc1.

MLA Handbook (7th Edition):

Kruger, D T. “Endocrine responsiveness in estrogen receptor-positive breast cancer: Search for biomarkers associated with treatment failure.” 2020. Web. 16 Apr 2021.

Vancouver:

Kruger DT. Endocrine responsiveness in estrogen receptor-positive breast cancer: Search for biomarkers associated with treatment failure. [Internet] [Doctoral dissertation]. NARCIS; 2020. [cited 2021 Apr 16]. Available from: https://research.vumc.nl/en/publications/88343427-dce7-4622-b8ae-82b6449bbcc1 ; urn:nbn:nl:ui:31-88343427-dce7-4622-b8ae-82b6449bbcc1 ; 88343427-dce7-4622-b8ae-82b6449bbcc1 ; urn:nbn:nl:ui:31-88343427-dce7-4622-b8ae-82b6449bbcc1 ; https://research.vumc.nl/en/publications/88343427-dce7-4622-b8ae-82b6449bbcc1.

Council of Science Editors:

Kruger DT. Endocrine responsiveness in estrogen receptor-positive breast cancer: Search for biomarkers associated with treatment failure. [Doctoral Dissertation]. NARCIS; 2020. Available from: https://research.vumc.nl/en/publications/88343427-dce7-4622-b8ae-82b6449bbcc1 ; urn:nbn:nl:ui:31-88343427-dce7-4622-b8ae-82b6449bbcc1 ; 88343427-dce7-4622-b8ae-82b6449bbcc1 ; urn:nbn:nl:ui:31-88343427-dce7-4622-b8ae-82b6449bbcc1 ; https://research.vumc.nl/en/publications/88343427-dce7-4622-b8ae-82b6449bbcc1

28. Kruger, D.T. Endocrine responsiveness in estrogen receptor-positive breast cancer: Search for biomarkers associated with treatment failure.

Degree: 2020, NARCIS

Subjects/Keywords: breast cancer; endocrine resistance; tamoxifen; everolimus; PI3K pathway

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Kruger, D. T. (2020). Endocrine responsiveness in estrogen receptor-positive breast cancer: Search for biomarkers associated with treatment failure. (Doctoral Dissertation). NARCIS. Retrieved from https://research.vu.nl/en/publications/5837e146-e5eb-4e45-aeae-655bb79768c1 ; urn:nbn:nl:ui:31-5837e146-e5eb-4e45-aeae-655bb79768c1 ; 5837e146-e5eb-4e45-aeae-655bb79768c1 ; 1871.1/5837e146-e5eb-4e45-aeae-655bb79768c1 ; urn:nbn:nl:ui:31-5837e146-e5eb-4e45-aeae-655bb79768c1 ; https://research.vu.nl/en/publications/5837e146-e5eb-4e45-aeae-655bb79768c1

Chicago Manual of Style (16th Edition):

Kruger, D T. “Endocrine responsiveness in estrogen receptor-positive breast cancer: Search for biomarkers associated with treatment failure.” 2020. Doctoral Dissertation, NARCIS. Accessed April 16, 2021. https://research.vu.nl/en/publications/5837e146-e5eb-4e45-aeae-655bb79768c1 ; urn:nbn:nl:ui:31-5837e146-e5eb-4e45-aeae-655bb79768c1 ; 5837e146-e5eb-4e45-aeae-655bb79768c1 ; 1871.1/5837e146-e5eb-4e45-aeae-655bb79768c1 ; urn:nbn:nl:ui:31-5837e146-e5eb-4e45-aeae-655bb79768c1 ; https://research.vu.nl/en/publications/5837e146-e5eb-4e45-aeae-655bb79768c1.

MLA Handbook (7th Edition):

Kruger, D T. “Endocrine responsiveness in estrogen receptor-positive breast cancer: Search for biomarkers associated with treatment failure.” 2020. Web. 16 Apr 2021.

Vancouver:

Kruger DT. Endocrine responsiveness in estrogen receptor-positive breast cancer: Search for biomarkers associated with treatment failure. [Internet] [Doctoral dissertation]. NARCIS; 2020. [cited 2021 Apr 16]. Available from: https://research.vu.nl/en/publications/5837e146-e5eb-4e45-aeae-655bb79768c1 ; urn:nbn:nl:ui:31-5837e146-e5eb-4e45-aeae-655bb79768c1 ; 5837e146-e5eb-4e45-aeae-655bb79768c1 ; 1871.1/5837e146-e5eb-4e45-aeae-655bb79768c1 ; urn:nbn:nl:ui:31-5837e146-e5eb-4e45-aeae-655bb79768c1 ; https://research.vu.nl/en/publications/5837e146-e5eb-4e45-aeae-655bb79768c1.

Council of Science Editors:

Kruger DT. Endocrine responsiveness in estrogen receptor-positive breast cancer: Search for biomarkers associated with treatment failure. [Doctoral Dissertation]. NARCIS; 2020. Available from: https://research.vu.nl/en/publications/5837e146-e5eb-4e45-aeae-655bb79768c1 ; urn:nbn:nl:ui:31-5837e146-e5eb-4e45-aeae-655bb79768c1 ; 5837e146-e5eb-4e45-aeae-655bb79768c1 ; 1871.1/5837e146-e5eb-4e45-aeae-655bb79768c1 ; urn:nbn:nl:ui:31-5837e146-e5eb-4e45-aeae-655bb79768c1 ; https://research.vu.nl/en/publications/5837e146-e5eb-4e45-aeae-655bb79768c1


Leiden University

29. Schneider, T.C. Novel treatments for advanced thyroid cancer and elucidation of biomarkers.

Degree: 2018, Leiden University

  In this thesis we describe the latest developments in the field of advanced thyroid cancer. Several clinical trials with sorafenib and everolimus were performed.… (more)

Subjects/Keywords: Thyroid cancer; Sorafenib; Everolimus; Clinical trial; Targeted therapy; Pharmacokinetics

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Schneider, T. C. (2018). Novel treatments for advanced thyroid cancer and elucidation of biomarkers. (Doctoral Dissertation). Leiden University. Retrieved from http://hdl.handle.net/1887/66672

Chicago Manual of Style (16th Edition):

Schneider, T C. “Novel treatments for advanced thyroid cancer and elucidation of biomarkers.” 2018. Doctoral Dissertation, Leiden University. Accessed April 16, 2021. http://hdl.handle.net/1887/66672.

MLA Handbook (7th Edition):

Schneider, T C. “Novel treatments for advanced thyroid cancer and elucidation of biomarkers.” 2018. Web. 16 Apr 2021.

Vancouver:

Schneider TC. Novel treatments for advanced thyroid cancer and elucidation of biomarkers. [Internet] [Doctoral dissertation]. Leiden University; 2018. [cited 2021 Apr 16]. Available from: http://hdl.handle.net/1887/66672.

Council of Science Editors:

Schneider TC. Novel treatments for advanced thyroid cancer and elucidation of biomarkers. [Doctoral Dissertation]. Leiden University; 2018. Available from: http://hdl.handle.net/1887/66672


Université Paris-Sud – Paris XI

30. Lemaitre, Florian. Optimisation des thérapeutiques immunosuppressives par méthode pharmacologique. : Optimization of immunosuppressive therapy using pharmacological method.

Degree: Docteur es, Pharmacologie expérimentale et clinique, 2014, Université Paris-Sud – Paris XI

 Les immunosuppresseurs sont des médicaments ayant démontré leur efficacité dans la prévention du rejet de transplantation d’organe solide. Néanmoins, ces médicaments présentent une importante variabilité… (more)

Subjects/Keywords: Immunosuppresseurs; Everolimus; Tacrolimus; Transplantation; Pharmacocinétique; Pharmacodynamie; Suivi thérapeutique pharmacologique; Pharmacocinétique de population; Lymphocytes; Cellules mononuclées; Intracellulaire; Immunosuppressive drugs; Everolimus; Tacrolimus; Transplantation; Pharmacokinetics; Pharmacodynamics; Therapeutic drug monitoring; Population pharmacokinetics; Lymphocytes; Peripheral blood mononuclear cells; Intracellular

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Lemaitre, F. (2014). Optimisation des thérapeutiques immunosuppressives par méthode pharmacologique. : Optimization of immunosuppressive therapy using pharmacological method. (Doctoral Dissertation). Université Paris-Sud – Paris XI. Retrieved from http://www.theses.fr/2014PA114832

Chicago Manual of Style (16th Edition):

Lemaitre, Florian. “Optimisation des thérapeutiques immunosuppressives par méthode pharmacologique. : Optimization of immunosuppressive therapy using pharmacological method.” 2014. Doctoral Dissertation, Université Paris-Sud – Paris XI. Accessed April 16, 2021. http://www.theses.fr/2014PA114832.

MLA Handbook (7th Edition):

Lemaitre, Florian. “Optimisation des thérapeutiques immunosuppressives par méthode pharmacologique. : Optimization of immunosuppressive therapy using pharmacological method.” 2014. Web. 16 Apr 2021.

Vancouver:

Lemaitre F. Optimisation des thérapeutiques immunosuppressives par méthode pharmacologique. : Optimization of immunosuppressive therapy using pharmacological method. [Internet] [Doctoral dissertation]. Université Paris-Sud – Paris XI; 2014. [cited 2021 Apr 16]. Available from: http://www.theses.fr/2014PA114832.

Council of Science Editors:

Lemaitre F. Optimisation des thérapeutiques immunosuppressives par méthode pharmacologique. : Optimization of immunosuppressive therapy using pharmacological method. [Doctoral Dissertation]. Université Paris-Sud – Paris XI; 2014. Available from: http://www.theses.fr/2014PA114832

[1] [2]

.